In vivo studies on the antitumor effect of cis-dichlorodiammineplatinum(II) against transplantable ovarian adenocarcinoma cells of the rat.
Both prolongation of survival and inhibition of tumor growth were observed in rats inoculated with 5 X 10(5) cloned ovarian adenocarcinoma (ROT68/C1) cells when they were administered intraperitoneally with cis-dichlorodiammineplatinum(II) (Cisplatin) at doses of from 1 to 4 mg/kg body wt every 3 weeks or one-third of the dose every week. However, the effects were not dose-schedule dependent and administration of 2 mg/kg every 3 weeks appeared to be the most effective. In contrast to nontreated controls, rats treated with Cisplatin developed both degeneration and necrosis particularly in tumor cells located around the capillaries, and thrombus formation was detected on the inside of many capillaries. Severe nephro- and hepatotoxicities were demonstrated after four courses of Cisplatin administration at doses of 2 mg/kg or more every 3 weeks.
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D000818:Animals; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains
D002945:Cisplatin